Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight)schedule.
A prescribed-only medication, Qsymia works in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
The company is planning to continue the certification of Qsymia, which is already approved in the US, and add them to the retail pharmacy network.
To view the retail pharmacies’ interactive map for the nearest certified retail pharmacies, the healthcare providers or Qsymia patients can enter a ZIP code.
Vivus president Peter Tam said that the start of a new process simplifies prescribing and improves access for patients in need of Qsymia, an effective and well-tolerated treatment for chronic weight management.
"This expansion, along with ongoing advancements in insurance coverage and reimbursement, will improve access to Qsymia for millions of patients with obesity," Tam added.